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Abstract 
Sex hormone concentrations of eumenorrheic women typically fluctuate across the menstrual cycle and can 
affect neural function such that estrogen has neuroexcitatory effects, and progesterone induces inhibition. 
However, the effects of these changes on corticospinal and intracortical circuitry and the motor performance of 
the knee extensors are unknown. The present two-part investigation aimed to 1) determine the measurement 
error of an exercise task, transcranial magnetic stimulation (TMS)-, and motor nerve stimulation (MNS)-derived 
responses in women ingesting a monophasic oral contraceptive pill (hormonally-constant) and 2) investigate 
whether these measures were modulated by menstrual cycle phase (MCP), by examining them before and after 
an intermittent isometric fatiguing task (60% of maximal voluntary contraction, MVC) with the knee extensors 
until task failure in eumenorrheic women on days 2, 14, and 21 of the menstrual cycle. The repeatability of 
neuromuscular measures at baseline and fatigability ranged between moderate and excellent in women taking 
the oral contraceptive pill. MVC was not affected by MCP (P = 0.790). Voluntary activation (MNS and TMS) 
peaked on day 14 (P = 0.007 and 0.008, respectively). Whereas corticospinal excitability was unchanged, short-
interval intracortical inhibition was greatest on day 21 compared with days 14 and 2 (P < 0.001). Additionally, 
time to task failure was longer on day 21 than on both days 14 and 2 (24 and 36%, respectively, P = 0.030). The 
observed changes were larger than the associated measurement errors. These data demonstrate that 
neuromuscular function and fatigability of the knee extensors vary across the menstrual cycle and may influence 
exercise performance involving locomotor muscles. 
NEW & NOTEWORTHY The present two-part study first demonstrated the repeatability of transcranial 
magnetic stimulation- and electrical motor nerve stimulation-evoked variables in a hormonally constant female 
population. Subsequently, it was demonstrated that the eumenorrheic menstrual cycle affects neuromuscular 
function. Changing concentrations of neuroactive hormones corresponded to greater voluntary activation on 
day 14, greater intracortical inhibition on day 21, and lowest fatigability on day 21. These alterations of knee 
extensor neuromuscular function have implications for locomotor activities. 
INTRODUCTION 
The cyclical changes in concentrations of multiple sex hormones, including estrogen and progesterone (55), 
across the eumenorrheic menstrual cycle can affect central nervous system (CNS) function due to their ability to 
cross the blood-brain barrier (62). In vitro models have shown direct evidence for the effect of sex hormones on 
neuronal function. For instance, estradiol (an estrogenic steroid hormone) binds to estrogen receptor-α (ERα) 
sites on γ-aminobutyric acid (GABA)-mediated neurons, causing an attenuation in GABA synthesis and release 
(54, 70). Additionally, estrogen potentiates the effects of excitatory glutamatergic [both N-methyl-d-aspartate 
(NMDA) and non-NMDA] receptors (61), resulting in a net excitatory effect. Additionally, estrogen has been 
shown to decrease firing thresholds and increase discharge frequency of cerebral neurons (58, 72). On the 
contrary, progesterone has a net inhibitory effect on the nervous system, as the activity and effects of GABA are 
potentiated, leading to decreased neuronal discharge rate (60) and increased inhibition of pyramidal neurons in 
rats (37). Some evidence also suggests that the presence of progesterone directly antagonizes estrogenic actions 
by lowering the available ERα and ERβ receptor numbers on various sites of neuronal cells (47). Indeed, as Smith 
and Woolley (61) outlined, the neurosteroidal actions of hormones act on the neurotransmitter receptors. Thus, 
given that GABAergic and glutamatergic synapses are located within the motor cortex (43), a hormonal effect 
would be expected. 
The differential effect of estrogen and progesterone concentrations on indexes of nervous system excitability 
has also been established in humans. Transcranial magnetic stimulation (TMS) studies show increased 
intracortical excitability and reduced intracortical inhibition in the late-follicular phase, when estradiol 
concentration is high and progesterone low (56, 57), substantiating the alterations seen in the aforementioned 
in vitro studies. While these in vivo studies show clear changes in human CNS function, they were conducted in 
the resting upper limbs, specifically in hand muscles associated with fine motor control. However, properties of 
intracortical and corticospinal circuits vary between upper and lower limb projections (7, 15). Thus, the 
menstrual cycle-associated modulations in neural function of a small upper limb muscle group cannot be 
extrapolated to larger, lower limb muscle groups. Understanding how the menstrual cycle affects the neural 
control of large locomotor muscle groups has significant implications for everyday locomotive tasks, injury 
rehabilitation, and athletic performance. For instance, neuroplasticity following stroke (17) and strength training 
(71) are influenced by GABAergic inhibition. 
To date, there is minimal research investigating menstrual cycle-induced changes in the nervous system and 
motor function of the knee extensors (KE). Previous studies investigating motor function, such as the ability to 
produce maximum voluntary contraction force (MVC), are equivocal, with studies showing 8–23% greater 
maximal force with the KE midcycle (4, 53, 64). Multiple studies, however, report no difference in maximal 
strength (20, 24, 40, 46). The studies that have shown changes in maximal strength have suggested that 
mechanisms such as motor unit firing rates (65) and intracortical excitability (56, 57) could be contributing 
factors. However, the proposed mechanistic factors, and the neuromuscular response (e.g., MVC), have not 
been concurrently studied. Voluntary activation (VA) of the quadriceps muscle has been assessed using motor 
nerve stimulation twice with no menstrual cycle effect shown (40, 46). However, as it is thought that the 
assessment of VA using TMS (VATMS) reflects the ability of the motor cortex to activate the motor units within 
the target muscle group (68), if supraspinal properties are modulated by the menstrual cycle (56, 57), 
VATMS could provide a more appropriate measure to discern whether the ability to voluntarily activate the KE is 
affected. 
Other aspects of motor performance, such as performance fatigability (38), have also been studied throughout 
the menstrual cycle with inconclusive results. Sarwar et al. (53) showed that the KE of eumenorrheic women 
were less fatigable in the luteal phase during an electrically stimulated, isometric fatiguing protocol. However, 
this finding has not been corroborated with dynamic voluntary contractions performed with the KE (21, 40). 
Additionally, none of the aforementioned studies were open-ended, with a fatigue index calculated after a set 
amount of time/contractions. Thus, due to the causes of fatigability being task specific (66), discrepancies in the 
aforementioned investigations could have been due to the differences in fatiguing protocols used and their 
respective limiting factors. 
The effect of hormonal fluctuations on neuromuscular function and fatigability of the KE remains unclear. 
Conflicting literature exists for the majority of neuromuscular variables despite a rationale for change based on 
neuroendocrine and upper limb studies. The inclusion of statistical measures of error is recommended for 
investigations utilizing methods of neurostimulation to inform the contribution of random variation to any 
modifications in neuromuscular function (29). Therefore, the present investigation recruited a population of 
monophasic oral contraceptive (mOCP) users to discern test-retest repeatability of neuromuscular function 
measures without the influence of endogenous hormones (Study A). The consistent dosage of exogenous 
estrogen and progesterone in the mOCP precludes ovulation (28), creating a physiological environment in which 
the effects of endogenous hormones are negated. Thereafter, Study B aimed to investigate KE neuromuscular 
function and fatigability across the menstrual cycle. It was hypothesized that when estrogen levels increased 
(and progesterone remained low) from day 2 to day 14, maximum force production would concomitantly rise 
alongside a reduction in intracortical inhibition and an increase in VA. Second, it was hypothesized that the rise 
in progesterone from day 14 to day 21 would occur alongside a reversal in these changes and improved time to 
task failure (TTF). 
METHODS 
Ethical Approval 
This study received institutional ethical approval from the Northumbria University Health and Life Sciences 
Research Ethics Committee (HLSPA301116) and was conducted according to all aspects of the Declaration of 
Helsinki, apart from registration in a database. Participants provided written, informed consent to volunteer for 
the study. 
Participants 
A total of 30 participants volunteered to participate in the study. Fifteen mOCP users (age: 23 ± 2 yr; stature: 
170 ± 6 cm; mass: 70.6 ± 8.5 kg) and 15 eumenorrheic women (age: 25 ± 4 yr; stature: 169 ± 6 cm; mass: 
68.3 ± 7.8 kg; mean cycle duration: 29 ± 3 days, range: 24–34 days). The mOCPs reported taking a mOCP for at 
least 6 mo as prescribed (i.e., a 7-day break after every 21-day pill consumption period), whereas eumenorrheic 
women reported having regular cycles without using any form of hormonal contraceptives for at least 6 mo. A 
full list of the mOCPs taken by participants is presented in Table 1. Participants arrived at the laboratory rested 






Table 1. mOCPs taken 
by participants in Study 
A 
     










Rigevidon 6 Ethinylestradiol 30 Levonorgestrel 150 
Cilest 3 Ethinylestradiol 35 Norgestimate 250 
Yasmin 2 Ethinylestradiol 30 Drospirenone 300 
Gedarel 1 Ethinylestradiol 20 Desogestrel 150 
Gedarel 1 Ethinylestradiol 30 Desogestrel 150 
Microgynon 1 Ethinylestradiol 30 Levonorgestrel 150 
Levest 1 Ethinylestradiol 30 Levonorgestrel 150 




Oral contraceptive users visited the laboratory three times, completing a familiarization and two experimental 
visits. Experimental visits were completed during the final 14 days of the pill cycle, with a minimum of 48 h 
between visits to allow recovery (13). The visits were identical to those described below for Study B; however, 
blood sampling was not performed, as it is established that endogenous hormone concentrations do not 
fluctuate throughout the consumption phase of the mOCP cycle (10). 
Study B. 
Eumenorrheic women visited the laboratory four times, completing a familiarization session before three 
experimental visits. Participants completed experimental visits on days 2 (D2, early follicular), 14 (D14, late 
follicular), and 21 (D21, midluteal) of the menstrual cycle. Testing days were counted from the onset of 
menstruation and, to verify menstrual cycle phase, fasted venous blood samples were taken between the hours 
of 0600 and 0900 on testing days to analyze serum estradiol and progesterone concentrations. The order of 
visits was pseudorandomized and counterbalanced to minimize order effects, with five participants beginning on 
each testing day (D2, D14 or D21). All testing visits occurred within the same menstrual cycle (order: D2, D14, 
D21), or two consecutive cycles (order: D14, D21, D2 or D21, D2, D14). Experimental visits consisted of a 
baseline neuromuscular assessment, intermittent, isometric contractions at 60% MVC until task failure, followed 
immediately by a post-task neuromuscular assessment. The intensity for the fatiguing task was likely far greater 
than the critical torque [~30% MVC (12)], and, therefore, an unsustainable intensity, with task failure 
attributable to decrements in neuromuscular function (1, 11). 
Experimental Procedures 
For Study B, upon arrival between the hours of 0600 and 0900, fasted venous blood samples were taken 
following 10 min of seated rest. Participants were then instructed to consume a typical breakfast and return to 
the laboratory at their designated testing time. The breakfast and time of testing were replicated (±1 h) for each 
experimental visit to control for diurnal variations in corticospinal excitability and maximal force production (63). 
Time of testing was also controlled for in Study A, with participants consuming the mOCP a constant time before 
trials to standardize circulating exogenous hormone concentrations between visits. In both studies, 
experimental sessions began with participants completing a standardized voluntary isometric contraction warm-
up (2 × contractions at 25, 50, and 75% perceived maximal effort) followed by a baseline neuromuscular 
assessment (described below). The fatiguing task involved sets of intermittent isometric contractions (3-s 
contraction, 2-s rest at 60% MVC) to task failure. Contractions were paced with an audible metronome to ensure 
the duty cycle was maintained. One set was defined as 11 submaximal contractions followed by a 3-s MVC with 
motor nerve stimulation (MNS) delivered at the peak force and 2 s post, lasting 1 min. Task failure was defined 
as an inability to reach the target force three times at any stage of the protocol. Rating of perceived exertion 
[RPE (6)] was recorded using a 6–20 scale following each MVC throughout the fatiguing task. Real-time visual 
force feedback using target forces set as percentages of maximum force was provided to participants on a 
computer screen to aid a constant force level. The post-task neuromuscular assessment began immediately 
following task failure. 
Neuromuscular assessments. 
Measures of neuromuscular function were assessed pre- and postexercise with MNS of the femoral nerve and 
TMS of the contralateral motor cortex at rest and during voluntary contractions of the right knee extensors. 
Preexercise neuromuscular assessments began with two practice MVCs to ensure potentiation of subsequent 
evoked measures, followed by three ~3-s MVCs, all separated by 30 s. During these three MVCs, MNS was 
delivered when peak force plateaued and then ~2 s after the MVC to measure voluntary activation (VAMNS) and 
potentiated twitch amplitude (Qtw.pot) of the knee extensors. Single-pulse TMS was subsequently delivered 
during two sets of five 3- to 5-s contractions at 100, 87.5, 75, 62.5, and 50% MVC, with 5-s rest between 
contractions and 10-s rest between sets, to determine VATMS (19). The TMS silent period (SP) was determined 
during the 50% MVC contraction of each set. Participants were instructed to maintain a constant force on the 
guideline and “push through the stimulation” (52). Finally, 10 single- and 10 paired-pulse TMS stimulations were 
delivered during a 10% MVC contraction in an alternate order to determine corticospinal excitability and short-
interval cortical inhibition (SICI), respectively. The neuromuscular assessment was repeated immediately 
postexercise. Measures of neuromuscular function (MVC, Qtw.pot, VAMNS) were measured within 30 s of task 
failure, and VATMS measured within 2–2.5 min, in an attempt to minimize the dissipation of fatigue. However it is 
possible that the sensitivity of these measures was compromised due to the rapid recovery of central fatigue 
postexercise (32). 
Force and electromyographical recordings. 
During assessments of neuromuscular function and fatiguing tasks, participants sat on a custom-built chair with 
knee and hip angles kept constant (both 90° flexion). A calibrated load cell (MuscleLab force sensor 300; 
Ergotest Technology, Porsgrunn, Norway) was attached via a noncompliant cuff positioned 2 cm superior to the 
ankle malleoli on the participants’ right leg, to measure knee extensor force (N). Surface Ag/AgCl electrodes 
(Kendall H87PG/F; Covidien, Mansfield, MA) were placed over the rectus femoris (RF), and biceps femoris (BF) 
muscles with a 2-cm interelectrode distance to record the compound muscle action potential (M-wave) elicited 
by the electrical stimulation of the femoral nerve, the motor-evoked potential (MEP) elicited by TMS, and the 
root-mean-square amplitude during isometric contractions (rmsEMG). Electrode placement was consistent with 
SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) guidelines (35), and a 
reference electrode was placed over the patella. Prior to placement, the skin-electrode contact area was 
cleaned using a 70% IPA alcohol wipe (FastAid; Robinson Healthcare, Worksop, UK). Signals were amplified: 
gain × 1,000 for EMG and × 300 for force (CED 1902; Cambridge Electronic Design, Cambridge, UK), bandpass 
filtered (EMG only: 20–2,000 Hz), digitized (5 kHz CED 1401, Cambridge Electronic Design), and analyzed offline 
(Spike2 v.8, Cambridge Electronic Design). 
Motor nerve stimulation. 
Single electrical stimuli (200 µs duration) were delivered to the right femoral nerve using a constant current 
stimulator (DS7AH Digitimer; Welwyn Garden City, UK) via adhesive surface electrodes (CF3200; Nidd Valley 
Medical, Harrogate, UK). The cathode was placed over the nerve, high in the femoral triangle, in the position 
that elicited the greatest twitch amplitude (Qtw) and M-wave in the RF at rest. The anode was placed halfway 
between the greater trochanter and the iliac crest. Optimum stimulus intensity was determined as the minimum 
current that elicited maximum values of Qtw and M-wave (Mmax) at rest. To ensure a supramaximal stimulus, the 
optimum stimulus intensity was increased by 30% and was not different between trials in either study (A: 
230 ± 61 vs. 241 ± 65 mA, P = 0.271; B: 233 ± 72, 244 ± 68, and 262 ± 67 mA, P = 0.125). 
Transcranial magnetic stimulation. 
Single and paired pulse stimuli (1 ms duration) were delivered to the contralateral (left) motor cortex via a 
concave double cone coil (110 mm diameter, maximum output 1.4 T) powered by two linked monopulse 
stimulators (Magstim Bistim and Magstim200; Magstim, Whitland, UK). Optimal coil placement was determined 
as the position that elicited the greatest RF MEP with concomitant smallest antagonist (BF) MEP during a 10% 
MVC at 50–70% stimulator output. This position was marked on the scalp with indelible marker to ensure 
consistent placement during trials. Stimulator intensity for VATMS was determined as the intensity that elicited 
the greatest superimposed twitch (SIT) during a contraction at 50% MVC. Stimulator intensity was increased in 
5% intervals from 50% stimulator output, and two stimuli were delivered during an ~5 s contraction, with the 
mean of two SITs recorded (9, 18). Mean stimulator intensity was not different between trials in either study (A: 
67 ± 10 vs. 66 ± 10%, P = 0.737; B: 63 ± 10, 63 ± 11 and 63 ± 12%, P = 0.984). The stimulator output activated a 
large proportion of the KE motoneuron pool at baseline in each experimental visit with no difference between 
trials in Study A (69 ± 35 vs. 68 ± 36% Mmax amplitude, P = 0.916) or Study B (61 ± 17, 57 ± 17, 55 ± 14% 
Mmax amplitude, P = 0.788). Small coactivation of the antagonist muscle (BF) was observed in response to TMS 
and did not differ between trials in Study A (0.60 ± 0.37 vs. 0.72 ± 0.53 mV, P = 0.106) or Study B (0.53 ± 0.39, 
0.71 ± 0.42 and 0.60 ± 0.34 mV, P = 0.211). 
Active motor threshold (aMT) was determined as the stimulator intensity that elicited a MEP of > 200 µV in 
three of five stimulations during a 10% MVC contraction. Stimulator intensity was increased in 5% steps from 
35% of stimulator output until a consistent MEP amplitude >200 μV was found. Thereafter, stimulus intensity 
was reduced in 1% steps until the lowest intensity to elicit a MEP of >200 μV was found. aMT was not different 
on any testing visit in Study A (40 ± 6 vs. 40 ± 7%, P = 0.746) or Study B (43 ± 9, 42 ± 8, and 43 ± 9%, P = 0.874). 
SICI was assessed with 10 paired and 10 single pulse stimulations delivered. Paired-pulse TMS consisted of a 
conditioning pulse at 70% of aMT and a test pulse at 120% aMT, with an interstimulus interval of 2 ms. All 
stimuli were delivered during a 10% contraction. This paradigm has previously been demonstrated to be the 
optimal configuration for eliciting SICI in the KE (8), and it has been used previously in our laboratory in male 
populations (31). Two sets of 10 stimuli were used, with a 10-s rest between contractions. 
Blood Sampling and Hormone Analysis (Study B only) 
Venous blood sampling was performed on the morning of each testing session. A 10-ml blood sample was drawn 
from an antecubital vein into a silica-coated tube by a trained phlebotomist and then left upright for 15 min to 
coagulate before centrifuging. Samples were centrifuged at 2,500 rpm for 10 min at room temperature (Allegra-
X22R; Beckman Coulter, Sykesville, MD). Using a 500- to 1,000-µl pipette, the supernatant serum was separated 
into three aliquots (~1000 µl each) and stored at −80°C until estradiol and progesterone analyses were 
performed. Total concentrations of 17β-estradiol and progesterone were measured in duplicate using hormone-
specific enzyme-linked immunoassay kits (Cayman Chemical, Ann Arbor, MI). All samples were analyzed using 
the ELISA technique with absorbance detection (wavelength 405 nm). The minimal estradiol and progesterone 
detection was 15 pg/ml and 7.5 pg/ml, respectively. To calculate 17β-estradiol and progesterone levels, a 
standard curve was plotted using eight standards against their absorbance. Using the mean absorbance from the 
duplicate of each sample, the concentration of the sample was interpolated directly from the standard curve. 
The coefficients of variation (CVs) for the ELISA kits, as provided by the manufacturer, were 8–12% for 17β-
estradiol, and 5–8% for progesterone. In one instance, the CV of a duplicate sample exceeded the 
manufacturer’s CV due to an excessively high (nonphysiological) reading in one well. Therefore, the lower of the 
two was used for data analysis. Participants’ hormonal profiles were deemed “acceptable” when a peak in 
progesterone concentration was observed during the luteal phase (D21) and an increase in 17β-estradiol was 
observed from D2 to D14. If neither peak was observed, participants were deemed anovulatory and excluded 
from further analyses. 
Data Analysis 
Voluntary activation using motor nerve stimulation was determined using the ITT (48) by comparing the 
amplitude of the superimposed twitch (SIT) with the amplitude of the potentiated resting twitch (Qtw.pot) using 
the following formula: VAMNS (%) = (1 – [SIT ÷ Qtw.pot]) × 100]. VA using TMS was assessed during two sets of 
contractions at 100, 87.5, 75, 62.5, and 50% MVC (19). Single-pulse TMS was delivered during each contraction, 
and the linear regression between SIT amplitude and contraction intensity was extrapolated to the y-intercept 
to obtain an estimated resting twitch (ERT; 68). To achieve significant linearity (P < 0.05), a total of 4 of 300 SITs 
across all trials in Study A were excluded (1.3%), which led to 4 regressions containing 9 data points rather than 
10 (1 preexercise, 3 postexercise). In Study B, 6 of 870 SITs were excluded from all linear regressions (0.7%), 
meaning that there were 86 10-point regressions, 3 9-point regressions, and 1 8-point regression used to 
estimate resting twitches. Mean r2 values for ERTs in Study A were 0.94 ± 0.04 preexercise vs. 0.94 ± 0.04 
postexercise and in Study B were 0.92 ± 0.05 preexercise, and 0.89 ± 0.07 postexercise. The SIT during 100% 
MVC was compared with the ERT using the following formula: VATMS (%) = (1 – [SIT ÷ ERT]) × 100. SICI was 
quantified as the percentage ratio between the amplitude of conditioned MEPs to the amplitude of 
unconditioned MEPs. Corticospinal excitability was determined by expressing the mean MEP amplitude during 
the 10% MVC as a percentage of Mmax. The rmsEMG was recorded during the middle 500-ms epoch of each 3-s 
contraction during the fatiguing task. rmsEMG was then expressed as a percentage of Mmax. For the data 
presented as %TTF, the MVC, VAMNS, and Qtw.pot for the nearest minute during the fatiguing protocols were 
taken, and the average rmsEMG for the nearest full set of contractions to the target percentage (i.e., 25, 50, or 
75% TTF) was taken; for 0 and 100% TTF, the first and last complete sets were used. All data analysis was 
performed offline. In Study B, despite rigorous familiarization and verbal encouragement, one participant failed 
to maintain the intermittent contractions for the required 3 s during the fatiguing task, thus invalidating the TTF 
duration. Therefore, it was deemed appropriate to remove the participant’s TTF duration and posttrial 
neuromuscular assessment from further analysis (n = 14); however, baseline data were included for statistical 
analysis (n = 15). 
Statistical Analysis 
Data are presented as mean ± SD within the text and figures. Normal Gaussian distribution of data was 
confirmed using the Kolmogorov-Smirnov test. If a violation was detected, the data were logarithmically 
transformed. The α for all statistical tests was set at P ≤ 0.05. 
For Study A, between-session and pre- to postexercise differences were explored using two-way (2 × 2) 
repeated-measures ANOVAs; if assumptions of sphericity were violated, then the Greenhouse-Geisser 
correction was applied. If significant main or interaction effects were detected, Bonferroni-corrected post hoc 
tests were performed. For between-session test-retest reliability, multiple indexes were calculated [paired-
samples t-tests, typical error, intraclass correlation coefficient (2, 36)] between the two time points. Within-
subjects variation was calculated as the standard deviation of the mean differences divided by the square root 
of 2 and termed typical error (TE) throughout the paper. Typical error was expressed as absolute raw values and 
as a percentage of the mean CV. Intraclass correlation coefficients (ICC3,1) were calculated according to Bland 
and Altman (5). ICC values were defined as follows: <0.5 = poor, 0.5–0.75 = moderate, 0.75–0.9 = good, 
>0.9 = excellent (45). Due to the ceiling effect (i.e., all values grouped close to 100%) associated with VAMNS and 
VATMS, the ICCs were not calculated (16, 67). 
For Study B, one-way repeated-measures ANOVAs were run for all pre-exercise-dependent variables to assess 
MCP changes in neuromuscular function and hormone concentrations. Sphericity was assessed using Mauchly’s 
test and, if necessary, was controlled using the Greenhouse-Geisser correction. Two-way repeated-measures 
ANOVAs were run using pre- and postexercise variables to obtain both fatigue and MCP × fatigue interaction 
effects. To explore potential differences in the fatigue profiles of neuromuscular and perceptual variables, two-
way repeated-measures ANOVAs were run, including data points from baseline and 25, 50, 75, and 100% of TTF. 
Significant main and interaction effects were explored using Bonferroni-corrected tests. 
RESULTS 
Study A 
Exercise performance and pre- to postexercise changes. 
The TTF was not different between experimental visits (560 ± 275 vs. 603 ± 357 s, respectively, P = 0.314). When 
assessing exercise-induced changes in neuromuscular function, the two-way ANOVAs detected no between-trial 
differences in change scores (trial × time interactions: P ≥ 0.331), therefore to assess the pre-to-post change, 
data from both visits were pooled. The MVC decreased pre- to postexercise (time effect: 507 ± 95 vs. 379 ± 85 
N; F1,14 = 136.66, P < 0.001, η2 = 0.91). Similarly, indices of contractile function (Qtw.pot and ERT) decreased pre- to 
posttrial (Qtw.pot: 169 ± 24 vs. 109 ± 21 N; F1,14 = 92.61, P < 0.001, η2 = 0.87; ERT: 120 ± 36 vs. 93 ± 28 
N; F1,14 = 19.07, P = 0.001, η2 = 0.56). Indices of VA also decreased pre- to posttrial: VAMNS (93.6 ± 3.2 vs. 
85.1 ± 6.8%; F1,14 = 36.60, P < 0.001, η2 = 0.72) and VATMS (94.6 ± 3.1 vs. 83.1 ± 10.6%; F1,14 = 20.82, P < 0.001, 
η2 = 0.60). Corticospinal excitability (MEP/Mmax) was not different pre- to postexercise (P = 0.057). There were no 
changes in SICI pre- to postexercise (80.8 ± 14.2 vs. 79.8 ± 13.9%, P = 0.667), whereas SP duration lengthened 
(189 ± 46 vs. 202 ± 50 ms, F1,14 = 5.49, P = 0.034, η2 = 0.28). Last, Mmax was not different pre- to postexercise 
(3.02 ± 1.19 vs. 2.81 ± 1.01 mV, P = 0.362). 
Reliability of neuromuscular measures. 
Preexercise data from mechanical variables (Table 2) showed good (ERT and TTF) and excellent (MVC and Qtw,pot) 
reliability. The TE and CV were also low for the majority of variables (CV ≤ 12.5%), except TTF (CV = 20.0%). 
Postexercise reliability (Table 2) was weaker but still interpreted as predominantly good (Qtw,pot and ERT) or 
excellent (MVC). These values were all poorer postexercise but remained relatively low (CV ≤ 14.9%). The 
relative reliability (ICCs) of the pre-to-post change was either moderate (MVC, ERT, and VAMNS) or good (Qtw,pot); 







Table 2. Reliability data for mechanical 
variables pre- and postexercise in 
Study A 
       
Measure Visit 1 Visit 2 P Bias TE CV 
(%) 
ICC (95% CI) 
MVC, N 
       




0.314 −9 23 4.5 0.96 (0.89–0.98) 




0.356 −8 24 6.2 0.94 (0.82–0.98) 




0.972 0 30 23.9 0.62 (0.18–0.85) 
Qtw.pot, N 
       




0.589 −2 9 5.0 0.90 (0.72–0.96) 




0.942 0 11 10.4 0.75 (0.40–0.91) 




0.643 −2 12 19.7 0.81 (0.53–0.93) 
ERT, N 
       




0.689 3 15 12.5 0.85 (0.62–0.95) 
    Post 94 ± 30 91 ± 27 0.605 3 14 14.9 0.79 (0.48–0.92) 




0.943 0 17 62.7 0.63 (0.20–0.86) 
VATMS, % 
       




0.679 −0.5 2.8 3.0 
 




0.406 −1.6 5.1 6.1 
 




0.573 1.1 5.2 45.4 0.78 (0.46–0.92) 
VAMNS, % 
       




0.834 −0.1 1.6 1.7 
 




0.942 −1.3 3.6 4.2 
 




0.390 1.2 3.7 43.2 0.66 (0.24–0.87) 




0.338 −43 117 20.0 0.88 (0.69–0.96) 
Values are means ± SD. Pre-to-Post change (Δ) is presented when a significant (P < 0.05) change was 
observed. CV, coefficient of variation; ICC, intraclass correlation coefficient; MVC, maximum voluntary 
contraction; Qtw.pot, potentiated quadriceps twitch; ERT, estimated resting twitch; VATMS, voluntary 
activation assessed with transcranial magnetic stimulation; VAMNS, voluntary activation assessed with 
motor nerve stimulation; TE, typical error; TTF, time to task failure. 
Surface EMG variables (Table 3) showed moderate (MEP/Mmax and SP) or good (SICI and Mmax) reliability 
preexercise but with larger test-retest CVs than mechanical variables (CV range: 9.2–30.1%). Postexercise 
reliability was similar to preexercise for most variables, with ICCs either moderate (MEP/Mmax and SP) or good 
(Mmax) and comparable CVs (range: 13.0–31.0%). Despite this, the postexercise reliability of SICI was poor 
(ICC = 0.42), which was further supported by a significant bias between visits 1 and 2 (−9.1%, P = 0.031). When 
the pre-to-post change was significant for a variable, i.e., SP, the relative reliability of change value was deemed 
poor (ICC = 0.44), with a high degree of random error (CV = 155.1%). 
 
Table 3. Reliability values for 
electromyographical data pre- and 
postexercise 
       
Measure Visit 1 Visit 2 P Bias TE CV, 
% 
ICC (95% CI) 
MEP/Mmax, % 
       




0.291 2.6 6.4 30.1 0.71 (0.34–0.89) 




0.677 0.9 5.4 31.0 0.72 (0.34–0.90) 
    Δ 
       
SICI, % 
       




0.148 −4.2 7.4 9.2 0.75 (0.42–0.91) 




0.031 −9.1 10.4 13.0 0.42 (0.00–0.75) 
    Δ 
       
Mmax, mV 
       




0.507 −0.12 0.48 15.9 0.86 (0.64–0.92) 




0.466 −0.14 0.50 17.8 0.79 (0.47–0.92) 
    Δ 
       
SP, ms 
       




0.791 −3 31 16.4 0.60 (0.24–0.82) 




0.947 −8 37 19.2 0.63 (0.19–0.86) 




0.815 2 20 155.1 0.44 (0.00–0.77) 
 
Values are means ± SD. Pre-to-Post change (Δ) is presented when a significant (P < 0.05) change was 
observed.CV, coefficient of variation; ICC, intraclass correlation coefficient; MEP, motor evoked 
potential,; MVC, maximum voluntary contraction; SICI, short-interval cortical inhibition; Mmax, maximum 
compound action potential; TE, typical error. 
Study B 
Hormonal profiles. 
Thirteen of 15 participants presented a regular hormonal profile (Table 4). Two participants had no 
increase in progesterone on D21; given the hypothesis that changing hormone concentrations would 
modulate neuromuscular function, and these participants did not exhibit any change in hormone 
concentrations, they were excluded from further statistical analyses. The repeated-measures ANOVAs 
showed an effect of MCP on 17β-estradiol (F1.4,19.5 = 3.55, P = 0.040, ηp2 = 0.18) and progesterone 
concentration (F = 1.0,14.1 = 8.35, P = 0.012, ηp2 = 0.37). Post hoc tests revealed that 17β-estradiol 
concentrations were greater on D14 than on D2 (P = 0.033) and greater on D21 than D2 (P = 0.029). 
Progesterone was greater on D21 than D2 and D14 (P = 0.011, and 0.012, respectively). 
Table 4. Group average concentrations for 17β-estradiol and 
progesterone across the 3 tested phases of the menstrual cycle 
   
 
Day 2 Day 14 Day 21 
17β-Estradiol, pg/ml 248 ± 129 328 ± 160* 341 ± 186* 
Progesterone, ng/ml 1.27 ± 0.50 1.38 ± 0.69 4.41 ± 
4.60*# 
E:P ratio 0.20 ± 0.13 0.28 ± 0.18 0.12 ± 
0.10*# 
Values are means ± SD. E:P, estrogen-to-progesterone; D, day of cycle. 
*greater than D2; 
#greater than D14. 
 
Baseline neuromuscular function. 
MVC force was unaffected by MCP (Fig. 1A, F1.4,16.8 = 0.15, P = 0.790, ηp2 = 0.01). Potentiated twitch force was 
also unchanged (Fig. 1B; F2,24 = 0.25, P = 0.782, ηp2 = 0.02); however, the SIT elicited by MNS was affected by 
MCP (F2,28 = 3.69, P = 0.040, ηp2 = 0.24), with greater SITs on D14 compared with D2 (mean difference: 2 N, P = 
0.031). The reduced SIT on D14 meant that VAMNS was affected by MCP (Fig. 1C; F2,28 = 9.23, P = 0.001, 
ηp2 = 0.44), with post hoc tests showing greater VAMNS on D14 than on D2 (mean difference: 1.9%, P = 0.007); 
however, there was no difference between D14 and D21 (mean difference: 1.0%, P = 0.059). VATMS was also 
affected by MCP (Fig. 1D; F2,28 = 5.89, P = 0.008, ηp2 = 0.33), with greater values on D14 than on D21 (mean 
difference: 3.0%, P = 0.016); however, D14 and D2 were not different (mean difference: 2.5%, P = 0.080). 
Despite the change in VATMS, neither of its constituent parts were altered by MCP: ERT (F1.3,15.3 = 0.25, P = 0.784, 
ηp2 = 0.02) and SIT elicited by TMS (F1.3,15.3 = 2.17, P = 0.136, ηp2 = 0.15). 
 
 
Fig. 1.Baseline neuromuscular measures across the 3 time points. A: maximum voluntary contraction (MVC). B: 
potentiated twitch force (Qtw.pot). C: voluntary activation assessed with motor nerve stimulation (VAMNS). D: VA assessed 
with transcranial magnetic stimulation (VATMS). E: superimposed MVS-evoked twitch during a maximum voluntary 
contraction (SITMNS). F: superimposed transcranial magnetic stimulation (TMS)-evoked twitch during a MVC (SITTMS). 
Individual data are shown with mean data overlaid as filled symbols and connecting line. 
As shown in Table 3, Mmax was unaffected by MCP (F2,28 = 0.24, P = 0.786, ηp2 = 0.02), nor was normalized MEP 
amplitude (Fig. 2A;F2,28 = 2.24, P = 0.129, ηp2 = 0.16). However, SICI was affected (Table 5 and Fig. 2B; F1.4, 
16.8 = 13.52, P < 0.001, ηp2 = 0.53), with post hoc tests showing greater inhibition on D21 than on D2 (mean 
difference: −10%, P = 0.048) and D14 (mean difference: −14%, P = 0.001). The prestimulus normalized rmsEMG 
activity was not different between MCPs (D2, 1.16 ± 0.43; D14, 1.07 ± 0.53; D21, 1.20 ± 0.64% 




Fig. 2.Transcranial magnetic stimulation evoked responses across the 3 testing time points. A: corticospinal 
excitability: motor evoked potential (MEP)/maximal muscle action potential (MMax). B: short-interval cortical 
inhibition (SICI). C: transcranial magnetic stimulation-evoked silent period. Individual data are shown with mean 




Table 5. Variables assessed throughout the pre- and post-exercise testing battery across the menstrual cycle 
 Day 2   Day 
14 
  Day 
21 








Pre Post Δ Pre Post Δ Pre Post Δ 1 × 3 
ANO
VA 
2 × 3 
ANOVA 

















−24% 0.790 <0.001 0.236 
SITM
NS, N 
9 ± 5# 11 ± 
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7 ± 4 10 ± 
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8 ± 4 11 ± 
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−7% 0.001 0.002 0.303 
SITTM
S, N 
6 ± 2 10 ± 
8 
67% 5 ± 3 9 ± 7 80% 7 ± 6 10 ± 
9 


























































































































Values are means ± SD. P values from the baseline ANOVA (1 × 3 repeated measures), and the pre- to postexercise 
ANOVA (2 × 3 repeated measures) are reported. When a significant effect of exercise was found, the Δ in a variable 
from pre- to postexercise was reported. Day, day of cycle; MVC, maximum voluntary contraction; SITMNS, 
superimposed twitch elicited by motor nerve stimulation; Qtw.pot, potentiated quadriceps twitch; VAMNS, voluntary 
activation assessed with motor nerve stimulation; SITTMS, superimposed twitch elicited by transcranial magnetic 
stimulation (TMS); ERT, estimated resting twitch; VATMS, voluntary activation assessed with TMS; MEP/Mmax, 
corticospinal excitability; SICI, short-interval cortical inhibition; SP, TMS evoked silent period; Mmax, maximum 
compound muscle action potential; TTF, time to task failure. 
 
Fatigability. 
Time to task failure during the intermittent, isometric, fatiguing task was significantly affected by MCP (Fig. 
3, F1.4, 14.8 = 6.89, P = 0.030, ηp2 = 0.32), with post hoc tests showing greater TTF on D21 than on D2 (mean 
difference: 187 s, P = 0.025). However, there was no difference between D21 and D14 (mean difference: 135 
s, P = 0.103) or D2 and D14 (P = 0.594). The two-way ANOVA (MCP × time) time effect showed that MVC 
decreased pre- to postexercise (F1,11 = 80.056, P < 0.001, ηp2 = 0.88), as did Qtw.pot (F1,11 = 123.53, P < 0.001, 
ηp2 = 0.92), VAMNS (F1,11 = 15.219, P = 0.002, ηp2 = 0.58), and VATMS (F1,11 = 13.99, P = 0.003, ηp2 = 0.56). SP also 
increased pre- to postexercise (F1,11 = 9.68, P = 0.010, ηp2 = 0.468). The MCP × time interaction effects for the 
aforementioned variables that changed pre- to postexercise indicated no difference between MCPs (all P ≥ 
0.128). The only exception to this was VATMS (F2,22 = 3.48, P = 0.049, ηp2 = 0.24); however, post hoc tests revealed 
that the differences were only apparent preexercise (as indicated above) and not postexercise (P ≥ 0.670). 
Despite no time effect (P = 0.578), SICI displayed a MCP × time interaction effect (F1.4, 15.0 = 5.26, P = 0.028, 
ηp2 = 0.32); however, the only differences were evident preexercise (as indicated above), with no post-exercise 
difference (P ≥ 0.247). 
 
 
Fig. 3.Time to task failure during the submaximal intermittent isometric fatiguing task at the 3 testing time 
points. Individual data are shown with mean data overlaid as filled symbols and connecting line. 
All variables measured during the fatiguing tasks (Fig. 4) demonstrated time effects (P ≤ 0.024); however, only 
some (MVC, Qtw.pot, and VAMNS) demonstrated an absence of MCP × time interaction effects (P ≥ 0.205). MVC 
(Fig. 4A) decreased progressively from baseline to 75% TTF (all intervals P ≤ 0.001); however, between 75 and 
100% TTF, no further decrease was observed (P = 0.776). A similar pattern was observed with Qtw.pot (Fig. 4B), 
with decreases exhibited until 50% TTF (both intervals P ≤ 0.009); however, between 50 and 100% TTF, 
Qtw.pot did not further decrease (P ≥ 0.593). VAMNS (Fig. 4C) demonstrated the inverse time course, with no 
change from 0 to 50% TTF (P ≥ 0.345) and then a progressive decrease from 50 to 100% TTF (P ≤ 0.034). rmsEMG 
(Fig. 4D) and RPE (Fig. 4E) exhibited phase × time interaction effects (P ≤ 0.032). RPE increased progressively 
throughout all trials (P ≤ 0.008). However, at 25% TTF, RPE was greater on D21 than on D14 (+2, P = 0.006); at 
50% TTF, D21 was greater than D2 (+2, P < 0.001); and at 75% TTF, D21 was greater than D2 (+1, P = 0.005). The 
only significant increase in rmsEMG was between 25 and 50% TTF (P = 0.003), and despite the phase × time 
interaction effect, no post hoc differences between phases were apparent (P ≥ 0.205). 
 
 
Fig. 4.Neuromuscular variables assessed at 25, 50, 75, and 100% time to task failure (TTF) throughout the 
fatiguing tasks in each menstrual cycle phase MCP. A: maximum voluntary contraction (MVC). B: potentiated 
quadriceps twitch (Qtw.pot). C: voluntary activation assessed with motor nerve stimulation (VAMNS). D: root mean 
squared EMG (rmsEMG). E: rating of perceived exertion (RPE). Data are means with standard deviation shown 
in A–D for the final point. Data are displayed as %baseline, although statistical analyses were performed on 
absolute data. Statistical differences (P < 0.05) are depicted by letters: abetween baseline and 25% 
TTF; bbetween 25 and 50% TTF; cbetween 50 and 75% TTF; dbetween 75 and 100% TTF; *between D21 and D14; 
#between D21 and D2. D2, white circles; D14, gray circles; D21, black circles. 
DISCUSSION 
The present investigation aimed to assess the influence of modulations in female sex hormones across the 
eumenorrheic menstrual cycle on neuromuscular function and fatigability. The data from Study A established 
repeatability of the measures in a hormonally constant female population (mOCP users). Subsequently, Study 
B showed that in eumenorrheic women the hormone-induced changes in neuromuscular function and 
fatigability across the menstrual cycle were greater than the associated error from hormonally constant women 
in Study A. Although one index of neuromuscular function (MVC) did not change, modulations in CNS control of 
muscle contraction were observed. Specifically, VA was greatest on D14, which was concurrent with an increase 
in the concentration of estrogen. Additionally, parallel to an increase in progesterone, SICI was greatest on D21. 
Time to task failure during the open-ended, intermittent, isometric protocol was greatest on D21 of the cycle. 
Collectively, the present data suggest that neuromuscular function and fatigability are modulated by the 
eumenorrheic menstrual cycle. 
Maximum Strength and VA Across the Menstrual Cycle 
There was no effect of MCP on MVC force. As mentioned, previous data regarding maximum voluntary strength 
across the menstrual cycle is equivocal. In agreement with the present study, multiple studies have shown no 
effect (24, 40, 46); however, several studies have shown that strength peaks midcycle (49, 53, 64). Previously, 
discrepancies such as the time of day (4) or variability in menstrual cycle duration, as well as the chosen days of 
the menstrual cycle for testing (27), have been used as explanatory reasons for this discrepancy. The present 
study controlled these factors within Study B by testing at the same time of day and confirming that participants 
were in the correct phase by serum hormone analysis, yet no effect of MCP was observed. 
Interestingly, Study B demonstrated changes in VA (assessed by both MNS and TMS) despite no change in MVC. 
VAMNS peaked on D14, and VATMS was greater on D14 compared with D21 (see Fig. 1). As Qtw.pot and ERT were not 
affected by MCP, these changes in VA were mediated by a decreased SIT amplitude on D14 in response to both 
motor nerve and motor cortical stimulation. This could indicate that there was a decrease in the capacity of the 
CNS to elicit extra force in response to stimulation. The TMS- and MNS-evoked SITs represent the extra force 
from motor units that the CNS is not able to voluntarily recruit or discharge at a sufficient rate (68). As 
acknowledged by Todd et al. (68), a change in SIT force could be caused by changes in the CNS altering 
activation of the motoneuron; therefore, changes within the motor cortex could provide an explanation for the 
change in VA. An alternative explanation could be the magnitude of the respective measurement errors of these 
variables. In StudyA, when hormones were controlled, the CVs of VAMNS (1.7%) and VATMS (3.0%) are lower than 
the TE for MVC (5.0%). Although changes seen in the present data set (i.e., the 1.8% increase in VAMNS between 
D2 and D14 or the 3.1% decrease in VATMS between D14 and D21) were similar to typical error, it could be the 
case that the increase in VA was not large enough to elicit a detectable increase in MVC due to its larger TE. 
Previous studies that have shown VAMNS not to change have used the central activation ratio (40, 46), which is 
less sensitive to change than the ITT (50). It is likely, therefore, that the magnitude of menstrual cycle effect on 
VAMNS and VATMS is marginally greater than the random error associated with the techniques used to assess it; 
thus, based on current evidence, the true effect is unclear. Also of note is the MCP × time interaction effect for 
VATMS, which would indicate that the magnitude of change from pre- to postexercise was different between 
MCPs. However, this appears to have been driven by the increased VATMS preexercise on D14, as there were no 
differences in postexercise values. Therefore, it is unlikely that participants experienced a greater degree of CNS 
adjustment following exercise during the late-follicular phase (D14). 
Corticospinal and Intracortical Function Across the Menstrual Cycle 
As mentioned, the increase in both measurements of VA on D14 (VAMNS and VATMS) could represent changes in 
supraspinal properties altering synaptic drive to the motoneuron pool across the menstrual cycle (51). To 
investigate the state of the corticospinal tract and motor cortex, the present study employed single- and paired-
pulse TMS. No menstrual cycle effect was observed on corticospinal excitability; however, intracortical inhibition 
was increased on D21. Single-pulse MEPs in the resting first dorsal interosseous muscle have previously been 
shown not to be affected by estrogen concentrations [day 1 vs. day 14 of the menstrual cycle (39)], and the 
present study extends this conclusion to the active knee extensors while demonstrating that the increase of 
progesterone concentrations on D21 is not concurrent with changes in corticospinal excitability. When paired-
pulse responses are considered, however, the increase in progesterone concentrations was concomitant with an 
~14% increase in SICI, which when considered with previous evidence (37, 59) was likely through potentiation of 
GABAA inhibition. Indeed, GABA agonist pharmacological interventions (e.g., baclofen and gabapentin) have 
shown similar changes (74). The difference between D14 and D21 demonstrated in Study B (14%) was double 
the measurement error of SICI observed in Study A (7%); however, there was no difference between D2 and D14 
(difference = 4%). Interestingly, SICI followed a similar pattern to the estrogen-to-progesterone (E/P) ratio 
(see Table 4), with the only significant change demonstrated on D21 concurrent to a decrease in the E/P ratio. 
Furthermore, the MCP × time interaction effect for SICI in Study B would suggest that intracortical inhibition is 
differentially modulated by exercise throughout the menstrual cycle. Although this is a concept that has been 
postulated before (23), and the present data appear to show this phenomenon, the interaction should be 
treated with caution, as the postexercise reliability of SICI in Study A was poor. A significant bias was observed 
(P = 0.031), with a poor ICC value (0.42); thus, a conclusion regarding MCP-specific changes in intracortical 
inhibition following exercise cannot be confidently made using the present data. 
The TMS SP, thought to partly reflect GABAB inhibitory mechanisms (14), was not affected by MCP, supporting 
previous data recorded in the FDI muscle (33). However, the conclusion that the menstrual cycle affects only 
GABAA neurotransmission cannot be made with the current data, as Yacyshyn et al. (73) showed that the SP has 
a large spinal contribution. Additionally, glutamatergic intracortical facilitation (ICF) was not measured in the 
present study, but it has previously been shown to be affected by the menstrual cycle, with augmented ICF 
demonstrated midcycle (56, 57). Although the causal link between intracortical function and VA is 
underresearched, it is possible that the adjustments of intracortical circuitry altered the capacity of TMS and 
MNS to evoke a SIT. For instance, if intracortical excitability was greatest on D14, there may have been a “ceiling 
effect,” meaning the stimulations were not able to induce additional excitation in the motor cortex, thus 
innervating fewer additive motor units during MVCs and evoking a smaller SIT, and the contrary occurring on 
D21, when inhibition was greatest. The modulation of neurotransmitters has previously shown to affect VA, with 
pharmacological increases in norepinephrine (44) and serotonin (42) resulting in a ~1–2% increase in VA. Indeed 
the effects of serotonin have been shown to be augmented by estrogen (3) and inhibited by progesterone (34). 
Therefore, it is possible that the modulation of inhibitory and facilitatory intracortical circuitry across the 
menstrual cycle might collectively contribute to the changes in VAMNS and VATMS. 
Fatigability Across the Menstrual Cycle 
Fatigability, as measured by the TTF of the open-ended fatiguing protocol, was lowest on D21 (i.e., greatest TTF), 
thus supporting the findings of Sarwar et al. (53), who showed that fatigue index was lowest in the luteal phase 
during a 3-min intermittent involuntary contraction protocol. The present data, however, contradict Janse de 
Jonge et al. (40), who showed no effect of MCP during voluntary or electrically evoked fatiguing protocols 
performed with the KE. The differences between tasks could explain these discrepancies. The voluntary task 
used by Janse de Jonge et al. (44) involved both dynamic knee extension and flexion rather than a single muscle 
group. This anisometric, multi-muscle group exercise likely elicits a different pattern of sensory afferent 
feedback (30) and was not open-ended like the present study, which could explain the discrepancies in 
fatigability. The same reasons might also apply to why the findings of DiBrezzo et al. (21) are inconsistent with 
those of the present study, who similarly demonstrated no menstrual cycle effect on fatigue during a set 
amount of dynamic contractions. Thus, the task employed in the present study likely permitted a greater degree 
of fatigue to develop, allowing the aforementioned MCP differences to be discerned. 
As widely acknowledged, fatigability has both physiological and perceptual components that interact to 
determine exercise tolerance (26, 66). The fatiguing task in the present study involved high-intensity (60% MVC), 
intermittent isometric contractions, which were assumed to be far greater than the critical torque [~30% MVC 
(12)] and were limited by decrements in neuromuscular adjustments (1, 11). With no MCP × time interaction 
effects displayed for neuromuscular variables (MVC, Qtw.pot, and VA), the degree of pre- to postexercise 
adjustment was not different between menstrual cycle phases. Accordingly, one hypothesis for why TTF was 
longer on D21 could be the influence of neurotransmitter systems on perceptions of fatigue. The present study 
measured GABAergic inhibition and demonstrated a large increase in SICI on D21 (Fig. 2B), and it has previously 
been shown that GABA can have antinociceptive properties (25) acting as an analgesic (41). Indeed, it has 
recently been postulated that “luteal analgesia” occurs in eumenorrheic women when progesterone is elevated, 
where the affective response to nociceptive pain is reduced due to alterations in functional connectivity in the 
emotional regulation network (69). Thus, it could be possible that the analgesic effects of enhanced GABAergic 
neurotransmission permitted participants to continue exercising for a longer period due to a lower perception of 
pain. However, more evidence is needed to explore the effects of GABAergic inhibition on exercise-induced 
fatigue. 
Further Considerations 
In StudyB it would appear that there was substantial between-subject variation in neuromuscular function and 
the changes across the menstrual cycle (Figs. 1–3). Potential explanations for this could be the large standard 
deviations in hormone concentrations at each time point (Table 4), which has been reported in previous 
investigations (55). Additionally, interindividual differences in hormone receptor numbers and sensitivity could 
contribute to the variation in changes across the menstrual cycle. In muscle tissue (22), expression of sex 
hormone receptors is altered by changing hormonal environments, which could conceivably occur in neuronal 
tissues such as the motor cortex; however, the present data cannot answer this research question. 
While serum hormones were quantified for the eumenorrheic women in Study B, the mOCP users’ serum 
hormone concentrations were not quantified in Study A. These data would have provided useful information 
about the measurement error of the sample; however, individual “meaningful” changes might differ between 
participants to achieve ovulation. 
Conclusion 
The present investigation demonstrated that, when neuroactive hormones are constant, women demonstrate 
stable neuromuscular function (Study A). In contrast, when eumenorrheic women were tested at three distinct 
phases of the menstrual cycle (Study B), the changing hormonal environment coincided with large changes in 
CNS function, which affected aspects of motor performance. Specifically, estrogen had neuroexcitatory effects 
that were associated with an increase in VA on D14, whereas progesterone’s neuroinhibitory effects were 
concurrent with an increased intracortical inhibition and decreased VA. Additionally, fatigability was modulated 
by MCP, with the greatest TTF seen on D21, concurrent with an increase in progesterone. Thus, the menstrual 
cycle elicits changes in neuromuscular function and fatigability in locomotor muscle of eumenorrheic women. 
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